ArticleCancer nanotechnology
Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment.
Article in Cancer nanotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 111 citations in OpenAlex.
- Recent Progress of Nanomedicine for the Synergetic Treatment of Radiotherapy (RT) and Photothermal Treatment (PTT).Cancers · 2025Review
- Advances in Ultrasmall Inorganic Nanoparticles for Nanomedicine: From Diagnosis to Therapeutics.ACS applied materials & interfaces · 2025Review
- Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Energy Transfer between AGuIX Nanoparticles and Photofrin under Light or X-ray Excitation for PDT Applications.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.International journal of molecular sciences · 2023Review
- Synthesis and characterization of GdScientific reports · 2023Article
- ACPSEM position paper: the safety of magnetic resonance imaging linear accelerators.Physical and engineering sciences in medicine · 2023Article
- Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine.International journal of molecular sciences · 2022Review
- A New Generation of Ultrasmall Nanoparticles Inducing Sensitization to Irradiation and Copper Depletion to Overcome Radioresistant and Invasive Cancers.Pharmaceutics · 2022Article
- Identification of Molecular Fragments in Equilibrium with Polysiloxane Ultrasmall Nanoparticles.Nanomaterials (Basel, Switzerland) · 2022Article
- Anti-BCMA Immuno-NanoPET Radiotracers for Improved Detection of Multiple Myeloma.Advanced healthcare materials · 2022Article
- Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics.Regenerative biomaterials · 2021Review
- Advances of Nanomedicine in Radiotherapy.Pharmaceutics · 2021Review
- Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma.International journal of molecular sciences · 2021Review
- Impact of superparamagnetic iron oxide nanoparticles on in vitro and in vivo radiosensitisation of cancer cells.Radiation oncology (London, England) · 2021Article
- Terbium-Based AGuIX-Design Nanoparticle to Mediate X-ray-Induced Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Application of Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2021Review
- Excretable, ultrasmall hexagonal NaGdFCancer nanotechnology · 2021Article
- Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AGuIX nanoparticles are formed of a polysiloxane network surrounded by gadolinium chelates. They present several characteristics. They are easy to produce, they present very small hydrodynamic diameters (<5 nm) and they are biodegradable through hydrolysis of siloxane bonds. Such degradation was evaluated in diluted conditions at physiological pH by dynamic light scattering and relaxometry. AGuIX nanoparticles are also known as positive contrast agents and efficient radiosensitizers. The aim of this paper is to compare their efficiency for magnetic resonance imaging and radiosensitization to those of the commercial gadolinium based molecular agent: DOTAREM®. An experiment with healthy animals was conducted and the MRI pictures we obtained show a better contrast with the AguIX compared to the DOTAREM® for the same amount of injected gadolinium in the animal. The better contrast obtained after injection of Aguix than DOTAREM® is due to a higher longitudinal relaxivity and a residential time in the blood circulation that is two times higher. A fast and large increase in the contrast is also observed by MRI after an intravenous injection of the AGuIX in 9 L gliosarcoma bearing rats, and a plateau is reached seven minutes after the injection. We established a radiotherapy protocol consisting of an irradiation by microbeam radiation therapy 20 minutes after the injection of a specific quantity of gadolinium. After microbeam radiation therapy, no notable difference in median survival time was observed in the presence or absence of gadolinium chelates (38 and 44 days respectively). In comparison, the median survival time is increased to 102.5 days with AGuIX particles showing their interest in this nanomedicine protocol. This remarkable radiosensitizing effect could be explained by the persistent tumor uptake of the particles, inducing a significant nanoscale dose deposition under irradiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.